Veradigm, Holmusk invest to close evidence gap in behavioral health

Veradigm and Holmusk, a global behavioral health real-world evidence company, jointly announced the next stage in its strategic collaboration. The collaboration draws on the strengths of each company to fuel innovation in behavioral health and create the evidence needed to move the field forward. In this new phase of the collaboration, cohorts of millions of behavioral health patients and related de-identified clinical data from Veradigm will be added to Holmusk’s NeuroBlu Database, a leading source for real-world data that shows how behavioral health care is delivered. Veradigm is also making an additional financial investment in Holmusk, building on a collaboration launched early this year, when Veradigm became the lead investor in Holmusk’s Series B financing round. “This strategic investment represents significant growth for our NeuroBlu Database, enabling us to move closer to our vision of creating a single source of truth for behavioral health,” said Nawal Roy, Holmusk’s founder and CEO. “This is a crucial step as we work to help eliminate the gaps in evidence, information, and learning that have held the behavioral health industry back from moving to an outcome-based reimbursement system and a learning healthcare system.” The collaboration expands Holmusk’s NeuroBlu Database by millions of patients. The NeuroBlu Database will now be able to power even more research and address challenging behavioral health questions that require the creation of targeted research cohorts.